Articles by Lori Clapper

  1. Mylan Signs Non-Exclusive Agreement To Market Venus' Antibiotic 9/9/2014

    Mylan Pharmaceuticals and Venus Pharma, a Germany based subsidiary of Venus Remedies, today announced a distribution-cum-out licensing partnership to market Venus’ antibiotic, Meropenem, in three European countries.

  2. EU Approves Allergan's Diabetic Macular Edema Treatment 9/5/2014

    Allergan, a multi-specialty health care company, announced Tuesday that the European Commission (EU) extended the marketing authorization for Ozurdex, which is the company’s 700 mcg intravitreal implant in applicator made for adults with visual impairment due to diabetic macular edema (DME). 

  3. Actavis Experiences Drug Shortage For Alzheimer's Drug 9/5/2014

    Actavis is struggling to supply its Alzheimer’s drug Namenda, after demand skyrocketed following the promotion of a slow-release version of the medicine ahead of the traditional pill’s patent expiration. In light of the high number of patients switching to the slow-release pill, Actavis decided to keeping selling the five-mg and ten-mg doses of the traditional pill through the end of the year, even though the company had originally planned to stop marketing the drug last month, according to the website Bidness Etc.

  4. AbbVie And Infinity Partner To Develop, Market New Cancer Drug 9/5/2014

    Infinity Pharmaceuticals and AbbVie announced Wednesday that they have entered a multimillion dollar global collaboration to develop and commercialize Infinity’s investigational cancer drug duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.

  5. Xention And Servier Partner For Phase 2 Development of Atrial Fibrillation Treatment 9/4/2014

    Xention, a Cambridge-based biopharmaceutical company, announced Monday that it has initiated the Phase 2 development of its lead atrial fibrillation (AF) program XEN-D0103.

  6. NIH To Begin Human Trials For Ebola Vaccine 9/2/2014

    The National Institutes of Health (NIH) announced last Thursday that it will begin human trials of an Ebola vaccine candidate this week.

  7. Biogen Idec Gets FDA Approval To Market Injectable MS Treatment In U.S. 8/20/2014

    The U.S. FDA has given Biogen Idec the go ahead to market Plegridy, its new injectable drug to treat adults with the chronic autoimmune disease Multiple Sclerosis (MS).

  8. Allergan Acquires Rights To LiRIS From TARIS Biomedical 8/20/2014

    Allergan, a multispecialty health care company, announced last week that it paid $67.5 million to TARIS Biomedical for the rights to LiRIS, a treatment for interstitial cystitis / bladder pain syndrome (IC/BPS) that is currently in Phase 2 trials.

  9. Mylan Launches Generic Cancer Therapy Treatment 8/13/2014

    Mylan announced Monday that it launched Capecitabine Tablets, its generic version of Genentech's Xeloda. The U.S. Food and Drug Administration (FDA) gave its final approval for Mylan’s Abbreviated New Drug Application (ANDA) for this product, which can to be taken as a monotherapy, adjuvant, or combination therapy for certain types of breast, colon, and colorectal cancers, the company said in an announcement.

  10. Collaborations Increasing To Reduce Development Risk, Study Reveals 8/13/2014
    Pharmaceutical and biotech companies are increasingly seeking ways to accelerate new drug development and lower the risks involved with drug development through strategic collaborations with developers and other service providers. Pharmaceutical and biotech R&D leaders discussed this and other industry issues in a recent roundtable discussion hosted by the Tufts Center for the Study of Drug Development (CSDD).